lilly tirzepatide shortage Compounders lose battle over Eli weight loss drug and FDA list Compounders suffer defeat in Eli

Many clients experience significant weight reduction, with an average weight loss of 15-20% of their body weight over the course of treatment

FDA-approved for the treatment of type 2 diabetes and to help those who have both conditions avoid major cardiovascular events Off-label use for weight loss in overweight patients may also be utilized to improve health outcomes, such as high blood pressure

Starting appetite-suppressing medications during this period raises legitimate concerns about whether milk supply will remain adequate and whether the mother's nutrition will support both her recovery and milk production

Risk of bias Two researchers (L.M